Optimi Health Receives Finished Product Test Results and Certificate Of Analysis for GMP Natural Psilocybin Extract
April 02, 2024 07:30 ET
|
Optimi Health Corp.
Optimi receives Certificate Of Analysis for GMP Natural Psilocybin Extract. Company has also completed the in-house encapsulation of 5mg & 10mg psilocybin.
Optimi Health Announces Third and Final Tranche of CAD $1,000,000 Secured for Debt Financing
November 02, 2023 07:30 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi Health” or the “Company”), a Canadian drug research and formulation...
Open For Business: Optimi Completes First Grow of Psilocybin Mushrooms and Introduces Head of Cultivation
May 25, 2022 09:00 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, May 25, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural,...
Optimi Health Submits Natural Psilocybin Combined Drug Delivery and Extraction Formulations for Provisional Patent
January 18, 2022 09:00 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom...
Optimi Health Natural Psilocybin Extraction Breakthrough Submitted for Provisional Patent Application
October 05, 2021 09:00 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional...